Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Small cap

NGL Fine-Chem profit more than doubles to ₹48 cr on broad-based demand

Consolidated revenue rose 36% for the full year, with domestic sales more than doubling and rest-of-world surging 78%.

4 earlier stories on NGL Fine-Chem Ltd.
Mkt cap₹1,847 cr
P/E38.38×
ROE7.39%
Debt / eq.0.27
Div yld0.06%
₹48.13 cr FY26 consolidated net profit, up 128% from prior year.

What's new

  • FY26 consolidated net profit jumped 128% to ₹48.13 crore; revenue climbed 36% to ₹500.95 crore.
  • India revenue more than doubled to ₹157.90 crore; rest-of-world sales grew 78% to ₹190.94 crore.
  • Board recommended a final dividend of ₹1.75 per share. Auditors gave an unmodified opinion.

Why this matters

NGL's results show demand isn't concentrated in any single geography. Domestic sales doubling alongside strong rest-of-world growth points to a product mix that's working in multiple markets at once. The unmodified audit opinion removes any governance overhang from the numbers.

What we're watching

  • Whether domestic growth sustains its current trajectory into FY27.
  • How Asia Pacific's 28% growth compares to sector peers.
  • The company's capacity expansion plans to support this demand.

The full read

NGL Fine-Chem had a strong year. Revenue rose 36% to ₹500.95 crore, but profit is the real story: it more than doubled to ₹48.13 crore, a 128% jump. The growth was broad. Domestic sales from India more than doubled to ₹157.90 crore. Rest-of-world revenue grew 78% to ₹190.94 crore. Even the slowest region, Asia Pacific, managed a 28% increase to ₹144.45 crore. Profit growing twice as fast as revenue suggests NGL is scaling more profitably. The company also recommended a ₹1.75 per share dividend and received a clean audit opinion. The demand isn't a one-market story. That's the part worth watching.

Questions answered

Which markets drove NGL Fine-Chem's revenue growth?
Domestic sales from India more than doubled to ₹157.90 crore. Rest-of-world revenue jumped 78% to ₹190.94 crore. Asia Pacific was the slowest-growing region at 28%.
How significant is the ₹48.13 crore profit figure?
Net profit of ₹48.13 crore is a 128% increase over the prior year, with revenue of ₹500.95 crore. The profit growth outpaced the revenue growth, indicating margin expansion.
What does the audit opinion say?
The auditors issued an unmodified opinion, which is a clean bill of health for the financial statements. This confirms the reliability of the reported numbers.
What is the dividend recommendation?
The board recommended a final dividend of ₹1.75 per share for FY26.
Mentioned: NGL Fine-Chem Ltd. · ₹500.95 cr revenue · ₹48.13 cr net profit
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

NGL Fine-Chem Ltd.

Pharmaceuticals
₹1,668 cr
P/E 34.67×

Latest quarter · Mar 2026

Sales₹149 cr
Net profit₹13 cr
Op. margin+14.3%
EPS₹21.83

Strength & growth

Debt / equity0.27×
Current ratio1.98×
Sales CAGR+17.9%
EPS CAGR+15.1%
  1. 22 May 2026 · 10:53 AM IST NGL Fine-Chem profit more than doubles to ₹48 cr on broad-based demand
  2. 51d ago NGL Fine-Chem profit jumps 128% as India revenue more than doubles
  3. 52d ago NGL Fine-Chem profit jumps 128% on strong domestic and export demand
  4. 52d ago NGL Fine-Chem profit surges 128% on broad geographic growth
  5. 52d ago NGL Fine-Chem profit surges 128% as Indian revenue doubles